|
1
|
Morawska L and Milton DK: It is time to
address airborne transmission of coronavirus disease 2019
(COVID-19). Clin Infect Dis: July 6, 2020 (Epub ahead of
print).
|
|
2
|
Zhang R, Li Y, Zhang AL, Wang Y and Molina
MJ: Identifying airborne transmission as the dominant route for the
spread of COVID-19. Proc Natl Acad Sci USA. 117:14857–18863.
2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Yan J, Grantham M, Pantelic J, Bueno de
Mesquita PJ, Albert B, Liu F, Ehrman S and Milton DK: EMIT
Consortium. Infectious virus in exhaled breath of symptomatic
seasonal influenza cases from a college community. Proc Natl Acad
Sci USA. 115:1081–1086. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Xie X, Li Y, Chwang AT, Ho PL and Seto WH:
How far droplets can move in indoor environments - revisiting the
Wells evaporation-falling curve. Indoor Air. 17:211–225.
2007.PubMed/NCBI View Article : Google Scholar
|
|
5
|
van Doremalen N, Bushmaker T, Morris DH,
Holbrook MG, Gamble A, Williamson BN, Tamin A, Harcourt JL,
Thornburg NJ, Gerber SI, et al: Aerosol and surface stability of
SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med.
382:1564–1567. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Chia PY, Coleman KK, Tan YK, Ong SWX, Gum
M, Lau SK, Lim XF, Lim AS, Sutjipto S, Lee PH, et al: Detection of
air and surface contamination by SARS-CoV-2 in hospital rooms of
infected patients. Nat Commun. 11(2800)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Guo ZD, Wang ZY, Zhang SF, Li X, Li L, Li
C, Cui Y, Fu RB, Dong YZ, Chi XY, et al: Aerosol and surface
distribution of severe acute respiratory syndrome coronavirus 2 in
hospital wards, Wuhan, China, 2020. Emerg Infect Dis. 26:1583–1591.
2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ong SWX, Tan YK, Chia PY, Lee TH, Ng OT,
Wong MSY and Marimuthu K: Air, surface environmental, and personal
protective equipment contamination by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient.
JAMA. 323:1610–1612. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Verdecchia P, Cavallini C, Spanevello A
and Angeli F: The pivotal link between ACE2 deficiency and
SARS-CoV-2 infection. Eur J Intern Med. 76:14–20. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bertram S, Heurich A, Lavender H, Gierer
S, Danisch S, Perin P, Lucas JM, Nelson PS, Pöhlmann S and Soilleux
EJ: Influenza and SARS-coronavirus activating proteases TMPRSS2 and
HAT are expressed at multiple sites in human respiratory and
gastrointestinal tracts. PLoS One. 7(e35876)2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sungnak W, Huang N, Bécavin C, Berg M,
Queen R, Litvinukova M, Talavera-López C, Maatz H, Reichart D,
Sampaziotis F, et al: SARS-CoV-2 entry factors are highly expressed
in nasal epithelial cells together with innate immune genes. Nat
Med. 26:681–687. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhou P, Yang XL, Wang XG, Hu B, Zhang L,
Zhang W, Si HR, Zhu Y, Li B, Huang CL, et al: A pneumonia outbreak
associated with a new coronavirus of probable bat origin. Nature.
579:270–273. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Qi F, Qian S, Zhang S and Zhang Z: Single
cell RNA sequencing of 13 human tissues identify cell types and
receptors of human coronaviruses. Biochem Biophys Res Commun.
526:135–140. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
ARDS Definition Task Force. Ranieri VM,
Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E,
Camporota L and Slutsky AS: Acute respiratory distress syndrome:
The Berlin definition. JAMA. 307:2526–2533. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gattinoni L, Coppola S, Cressoni M, Busana
M, Rossi S and Chiumello D: COVID-19 does not lead to a ‘typical’
acute respiratory distress syndrome. Am J Respir Crit Care Med.
201:1299–1300. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gattinoni L, Chiumello D, Caironi P,
Busana M, Romitti F, Brazzi L and Camporota L: COVID-19 pneumonia:
Different respiratory treatments for different phenotypes?
Intensive Care Med. 46:1099–1102. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Robba C, Battaglini D, Ball L, Patroniti
N, Loconte M, Brunetti I, Vena A, Giacobbe DR, Bassetti M, Rocco
PRM and Pelosi P: Distinct phenotypes require distinct respiratory
management strategies in severe COVID-19. Respir Physiol Neurobiol.
279(103455)2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lansbury L, Lim B, Baskaran V and Lim WS:
Co-infections in people with COVID-19: a systematic review and
meta-analysis. J Infect. 81:266–275. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Morens DM, Taubenberger JK and Fauci AS:
Predominant role of bacterial pneumonia as a cause of death in
pandemic influenza: Implications for pandemic influenza
preparedness. J Infect Dis. 198:962–970. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
20
|
Brundage JF: Interactions between
influenza and bacterial respiratory pathogens: Implications for
pandemic preparedness. Lancet Infect Dis. 6:303–312.
2006.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Chien YW, Klugman KP and Morens DM:
Bacterial pathogens and death during the 1918 influenza pandemic. N
Engl J Med. 361:2582–2583. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
MacIntyre CR, Chughtai AA, Barnes M, Ridda
I, Seale H, Toms R and Heywood A: The role of pneumonia and
secondary bacterial infection in fatal and serious outcomes of
pandemic influenza a(H1N1)pdm09. BMC Infect Dis.
18(637)2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Thindwa D, Garcia Quesada M, Liu Y,
Bennett J, Cohen C, Knoll MD, von Gottberg A, Hayford K and Flasche
S: Use of seasonal influenza and pneumococcal polysaccharide
vaccines in older adults to reduce COVID-19 mortality. Vaccine.
38:5398–5401. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Simpson S, Kay FU, Abbara S, Bhalla S,
Chung JH, Chung M, Henry TS, Kanne JP, Kligerman S, Ko JP and Litt
H: Radiological Society of North America Expert Consensus Statement
on Reporting Chest CT Findings Related to COVID-19. Endorsed by the
Society of Thoracic Radiology, the American College of Radiology,
and RSNA. Radiol Cardiothorac Imaging. 2(e200152)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Li W, Zhang B, Lu J, Liu S, Chang Z, Cao
P, Liu X, Zhang P, Ling Y, Tao K and Chen J: The characteristics of
household transmission of COVID-19. Clin Infect Dis: April 17, 2020
(Epub ahead of print).
|
|
26
|
Zhang J, Litvinova M, Liang Y, Wang Y,
Wang W, Zhao S, Wu Q, Merler S, Viboud C, Vespignani A, et al:
Changes in contact patterns shape the dynamics of the COVID-19
outbreak in China. Science. 368:1481–1486. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J,
Zhang W, Wang Y, Bao S, Li Y, et al: SARS-CoV-2 infection in
children. N Engl J Med. 382:1663–1665. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wu Z and McGoogan JM: Characteristics of
and important lessons from the coronavirus disease 2019 (COVID-19)
outbreak in China: Summary of a report of 72,314 cases From the
Chinese Center for Disease Control and Prevention. JAMA.
323:1239–1242. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z
and Tong S: Epidemiology of COVID-19 among children in China.
Pediatrics. 145(e20200702)2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Weng NP: Aging of the immune system: How
much can the adaptive immune system adapt? Immunity. 24:495–499.
2006.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Van Bever HP, Chng SY and Goh DY:
Childhood severe acute respiratory syndrome, coronavirus infections
and asthma. Pediatr Allergy Immunol. 15:206–209. 2004.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Saheb Sharif-Askari N, Saheb Sharif-Askari
F, Alabed M, Temsah MH, Al Heialy S, Hamid Q and Halwani R: Airways
expression of SARS-CoV-2 receptor, ACE2, and TMPRSS2 is lower in
children than adults and increases with smoking and COPD. Mol Ther
Methods Clin Dev. 18:1–6. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Götzinger F, Santiago-García B,
Noguera-Julián A, Lanaspa M, Lancella L, Calò Carducci FI,
Gabrovska N, Velizarova S, Prunk P, Osterman V, et al: COVID-19 in
children and adolescents in Europe: a multinational, multicentre
cohort study. Lancet Child Adolesc Health. 4:653–661.
2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Toubiana J, Poirault C, Corsia A, Bajolle
F, Fourgeaud J, Angoulvant F, Debray A, Basmaci R, Salvador E,
Biscardi S, et al: Kawasaki-like multisystem inflammatory syndrome
in children during the covid-19 pandemic in Paris, France:
Prospective observational study. BMJ. 369(m2094)2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Verdoni L, Mazza A, Gervasoni A, Martelli
L, Ruggeri M, Ciuffreda M, Bonanomi E and D'Antiga L: An outbreak
of severe Kawasaki-like disease at the Italian epicentre of the
SARS-CoV-2 epidemic: An observational cohort study. Lancet.
395:1771–1778. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Grasselli G, Pesenti A and Cecconi M:
Critical care utilization for the COVID-19 outbreak in Lombardy,
Italy: Early experience and forecast during an emergency response.
JAMA. 323:1545–1546. 2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Remuzzi A and Remuzzi G: COVID-19 and
Italy: What next? Lancet. 395:1225–1228. 2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Alhazzani W, Møller MH, Arabi YM, Loeb M,
Gong MN, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, et al:
Surviving sepsis campaign: guidelines on the management of
critically ill adults with Coronavirus Disease 2019 (COVID-19).
Intensive Care Med. 46:854–887. 2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Million M, Lagier JC, Gautret P, Colson P,
Fournier PE, Amrane S, Hocquart M, Mailhe M, Esteves-Vieira V,
Doudier B, et al: Early treatment of COVID-19 patients with
hydroxychloroquine and azithromycin: A retrospective analysis of
1061 cases in Marseille, France. Travel Med Infect Dis. 35:101738.
2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Hung IF, Lung KC, Tso EY, Liu R, Chung TW,
Chu MY, Ng YY, Lo J, Chan J, Tam AR, et al: Triple combination of
interferon beta-1b, lopinavir-ritonavir, and ribavirin in the
treatment of patients admitted to hospital with COVID-19: An
open-label, randomised, phase 2 trial. Lancet. 395:1695–1704.
2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Goldman JD, Lye DCB, Hui DS, Marks KM,
Bruno R, Montejano R, Spinner CD, Galli M, Ahn MY, Nahass RG, et
al: Remdesivir for 5 or 10 days in patients with severe Covid-19. N
Engl J Med: May 27, 2020 (Epub ahead of print).
|
|
42
|
Beigel JH, Tomashek KM, Dodd LE, Mehta AK,
Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, et
al: Remdesivir for the treatment of Covid-19 - Preliminary report.
N Engl J Med: May 22, 2020 (Epub ahead of print).
|
|
43
|
Deftereos SG, Giannopoulos G, Vrachatis
DA, Siasos GD, Giotaki SG, Gargalianos P, Metallidis S, Sianos G,
Baltagiannis S, Panagopoulos P, et al: Effect of colchicine vs
standard care on cardiac and inflammatory biomarkers and clinical
outcomes in patients hospitalized with coronavirus disease 2019:
The GRECCO-19 randomized clinical trial. JAMA Netw Open.
3(e2013136)2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Sciascia S, Aprà F, Baffa A, Baldovino S,
Boaro D, Boero R, Bonora S, Calcagno A, Cecchi I, Cinnirella G, et
al: Pilot prospective open, single-arm multicentre study on
off-label use of tocilizumab in patients with severe COVID-19. Clin
Exp Rheumatol. 38:529–532. 2020.PubMed/NCBI
|
|
45
|
Guaraldi G, Meschiari M, Cozzi-Lepri A,
Milic J, Tonelli R, Menozzi M, Franceschini E, Cuomo G, Orlando G,
Borghi V, et al: Tocilizumab in patients with severe COVID-19: a
retrospective cohort study. Lancet Rheumatol. 2:e474–e484.
2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Huet T, Beaussier H, Voisin O, Jouveshomme
S, Dauriat G, Lazareth I, Sacco E, Naccache JM, Bézie Y, Laplanche
S, et al: Anakinra for severe forms of COVID-19: A cohort study.
Lancet Rheumatol. 2:e393–e400. 2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Ledford H: Chloroquine hype is derailing
the search for coronavirus treatments. Nature.
580(573)2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Rosenberg ES, Dufort EM, Udo T,
Wilberschied LA, Kumar J, Tesoriero J, Weinberg P, Kirkwood J, Muse
A, DeHovitz J, et al: Association of treatment with
hydroxychloroquine or azithromycin with in-hospital mortality in
patients with COVID-19 in New York state. JAMA. 323:2493–2502.
2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
No clinical benefit from use of
hydroxychloroquine in hospitalised patients with COVID-19.
urihttps://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19simplehttps://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19.
Accessed June 5, 2020.
|
|
50
|
World Health Organization (WHO): WHO
discontinues hydroxychloroquine and lopinavir/ritonavir treatment
arms for COVID-19.WHO, Geneva, 2020. urihttps://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19simplehttps://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19.
Accessed July 4, 2020.
|
|
51
|
National Institutes of Health (NIH):
COVID-19 Treatment Guidelines: Coronavirus disease 2019 (COVID-19)
treatment guidelines. NIH, Bethesda, MD, 2020. urihttps://www.covid19treatmentguidelines.nih.gov/simplehttps://www.covid19treatmentguidelines.nih.gov/.
Accessed July 11, 2020.
|
|
52
|
RECOVERY Collaborative Group. Horby P, Lim
WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N,
Brightling C, Ustianowski A, et al: Effect of dexamethasone in
hospitalized patients with COVID-19: Preliminary report. N Engl J
Med: July 17, 2020 (Epub ahead of print).
|
|
53
|
Liu J, Zheng X, Huang Y, Shan H and Huang
J: Successful use of methylprednisolone for treating severe
COVID-19. J Allergy Clin Immunol. 146:325–327. 2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Yang Z and Liu J, Zhou Y, Zhao X, Zhao Q
and Liu J: The effect of corticosteroid treatment on patients with
coronavirus infection: A systematic review and meta-analysis. J
Infect. 81:e13–e20. 2020.PubMed/NCBI View Article : Google Scholar
|
|
55
|
World Health Organization (WHO): Draft
landscape of COVID-19 candidate vaccines. WHO, Geneva, 2020.
urihttps://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccinessimplehttps://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
Accessed September 28, 2020.
|
|
56
|
Antoniou K, Raghu G, Tzilas V and Bouros
D: Management of patients with interstitial lung disease in the
midst of COVID-19. Respiration. 99:625–627. 2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Antoniou K, Bolaki M, Bibaki E, Vasarmidi
E, Trachalaki A, Tsitoura E and Bouros D: COVID19 alert Do we know
our enemy? Pneumon. 33:25–27. 2020.
|
|
58
|
Bouros D: BCG vaccination and Covid-19
protection. Pneumon. 33:7–9. 2020.
|
|
59
|
Sampsonas F: Bacillus Calmette-Guerin:
Established and emerging roles for an old friend. Pneumon.
33:10–12. 2020.
|
|
60
|
Antoniadis A, Pechlivanidou R, Bouros E
and Bouros D: Stem cells and covid-19. Pneumon. 33:1–3. 2020.
|
